每经记者｜王琳 每经编辑｜董兴生 6月18日晚间，重药控股（000950.SZ，股价4.94元，市值85.37亿元）发布公告披露，其于6月18日收到公司控股股东重庆医药健康产业有限公司（以下简称 重庆医健）的告知函，获悉其股权结构拟发生变更。 具体来说，重庆医健的股东重庆渝富控股集团有限公司（以下简称重庆渝富）于6月18日在重庆联合产权交易所集团股份有限公司（以下简称重庆联交所） 公开挂牌转让重庆医健24%股权。 2024年全年，重庆医健实现营业收入和净利润分别为811.75亿元和4.14亿元；2025年第一季度，重庆医健的营业收入和净利润分别为207.57亿元和1.87亿元。 截至2025年一季度末，重庆医健的所有者权益为188.07亿元。 | | 以下数据出自年度审计报告 | | | | --- | --- | --- | --- | | 2024 (年度) | 营业收入 | 营业利润 | 浄利润 | | | 8117500. 21万元 | 57886. 30万元 | 41361. 24万元 | | | 资产总计 | 负债总计 | 所有者权益 | | | 6900556. 26万元 | 5042140.1 ...

中国医药健康产业股份有限公司股东大会会议文件 议案一 关于选举董事并确定其报酬标准的议案 中国医药健康产业股份有限公司股东大会会议文件 证券代码：600056 证券简称：中国医药 2025 年第三次临时股东大会 会议资料 2025 年 6 月 23 日 北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 以上议案，请各位股东审议。 各位股东： 经公司第九届董事会第 27 次会议审议通过，董事会同意将 提名潘臻先生为公司董事候选人的事项提交本次股东大会审议， 其任期自股东大会审议通过之日至第九届董事会届满。 候选人简历如下： 潘臻先生，61 岁，硕士研究生，高级工程师。 曾任中国通用技术（集团）控股有限责任公司总经理助理； 中国邮电器材集团有限公司董事长、党委书记；中国轻工业品进 出口集团有限公司董事长。 经公司第九届董事会第 27 次会议审议通过，结合公司的经营 效益等情况，拟确定潘臻先生在公司担任董事职务期间的报酬标 准为：每月税前固定报酬 7,500 元，年底根据其考核结果确定奖 金，每年税前报酬合计不超过 13 万。 ...

Group 1 - Libet has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds, valid for 12 months [1] - Dinglong plans to acquire an additional 8% stake in its subsidiary, increasing its ownership from 91.35% to 99.35% for a total price of 240 million yuan [1] - Longyuan Donggu has been designated as a supplier for a major automotive project, with an expected total sales amount of 450 to 500 million yuan over five years [14] Group 2 - Luoniushan reported a sales revenue of 100 million yuan in May, a year-on-year decrease of 11.45% [2] - Baoming Technology has secured a loan commitment of up to 7 million yuan for stock repurchase [2] - Xinhua Pharmaceutical has received approval for the listing of a new chemical raw material used in treating chronic heart failure and hypertension [3] Group 3 - China Minmetals announced a new contract amount of 396 billion yuan for the first five months of the year, a decrease of 22.2% year-on-year [7] - Zhongbei Communication's application for a specific stock issuance has been accepted by the Shanghai Stock Exchange [8] - Rongfa Nuclear Power plans to issue bonds not exceeding 1 billion yuan to repay debts and supplement working capital [9] Group 4 - Phoenix Optical plans to invest 8.5 million USD to establish a wholly-owned subsidiary in Vietnam for manufacturing optical products [11] - Xiamen Airport reported a passenger throughput of 2.4752 million in May, a year-on-year increase of 8.34% [12] - Weilan Biological has received a new veterinary drug registration certificate for a product aimed at treating canine allergies and inflammation [13] Group 5 - Shouxiangu has completed the registration of a health food product that claims to enhance immunity [13] - Xingye Yinxin's subsidiary has passed a resource reserve verification report, confirming significant mineral reserves [16] - Shaanxi Construction has won two major projects with a total contract value exceeding 2.8 billion yuan [18] Group 6 - Huari received a cash dividend of 50 million yuan from its subsidiary [20] - Zhongchu's deputy general manager has resigned due to governance arrangements [21] - Kexin Pharmaceutical's core product has received breakthrough therapy designation from the National Medical Products Administration [39]

证券代码：600056 证券简称：中国医药 公告编号：临 2025-044 号 中国医药健康产业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司海南通用三洋药业有限公司（以下简称"三洋药业"）收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的一份磷酸特地唑胺片（以下简称"该 药品"）《药品注册证书》，现将有关情况公告如下： 一、注册证书基本信息 药品名称：磷酸特地唑胺片 受理号：CYHS2400360 证书编号：2025S01687 剂型：片剂 规格：0.2g 上市许可持有人：海南通用三洋药业有限公司 （三）截至本公告披露日，该药品累计投入约 1,640 万元人民币（未经审计）。 （四）药品市场情况介绍 截至本公告披露日，除三洋药业外，国内已有北京福元医药股份有限公司、 南京正大天 ...

主持：关珊（股市广播FM95.3《走进机构大本营》） 嘉宾：莫小城（桓瑞天泽总经理） 最近医药板块的表现非常亮眼，创新药概念股更是一马当先。根据相关统计，年内万得创新药指数已经 大涨超过20%。港股方面的创新药指数涨幅更高，超过45%。亮眼的指数表现使得相关的ETF产品表现 水涨船高。目前，今年以来涨幅超过30%的创新药ETF越来越多，已经取代之前非常火热的人工智能、 机器人等板块，集体跻身到前十位置。 莫小城坚信，未来，中国医药行业，包括创新药企、医疗设备和中成药等，预计在全球舞台上将展现更 强的竞争力，行业增速加快。长期来看，中国有可能诞生全球最大的医药公司。 港股创新药市场表现更佳 2025年以来，港股创新药指数涨幅超过45%，远超A股创新药指数涨幅。这一差异主要归因于港股市场 的18A制度，对创新药公司的上市门槛宽松，许多优质创新药公司在港上市融资。同时之前多年港股创 新药公司持续下跌，估值相对便宜。 桓瑞天泽总经理莫小城认为，尽管医药板块年内涨幅显著，但这仅是开始。基于长期研究，他乐观预 期，中国医药行业，尤其是创新药领域，将迎来持续高增长和全球竞争力提升。港股与A股医药板块表 现差异中，港股因估值 ...

Summary of Key Points from the Conference Call Industry Overview - **Industry**: China Pharma and Biotech - **Focus**: Updates from ASCO 2025 regarding various cancer treatments, particularly in extensive stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC) Core Insights and Arguments 1. **Zai Lab's ZL-1310 (DLL3 ADC)**: - Reported a 68% overall response rate (ORR) in the dose escalation group (n=28) for ES-SCLC - Notable results in 2L patients: 67% ORR across doses (n=33) and 79% ORR in the 1.6 mg/kg group (n=14) [1][8] - Safety profile shows 23% Grade ≥3 treatment-related adverse events (TRAE) [1] - Potential for best-in-class (BIC) status, pending survival data [1] 2. **Innovent's IBI363 (PD-1/IL-2 bispecific)**: - High ORR of 37% and median progression-free survival (mPFS) of 9.3 months in squamous NSCLC patients who failed PD-(L)1 treatment [2][10] - Efficacy significantly surpasses Dato-Dxd (Daiichi Sankyo/AstraZeneca) in cross-trial comparisons [2] 3. **Hengrui's SHR-1826 (c-met ADC)**: - Demonstrated a 29% confirmed ORR and 40% unconfirmed ORR in NSCLC patients with c-met alterations [2][10] - C-met alterations are prevalent in 10-60% of NSCLC globally, indicating a substantial market opportunity [2] 4. **Market Potential**: - NSCLC has a total addressable market (TAM) of approximately US$30 billion, with 1L treatment representing over 60% of this market [4] - Breast cancer market estimated at US$35 billion, with emerging products but no significant efficacy improvements over leading global products [4] 5. **Investment Ratings**: - Outperform ratings maintained for Akeso, Hansoh, Innovent, and Hengrui [6] - Market-Perform ratings for BeiGene, CSPC, Sino Biopharm, and Zai Lab [6] Additional Important Content - All updates are derived from Phase 1 trials, typically lacking control groups [3] - The competitive landscape includes various other companies and products, with specific mentions of Akeso, 3S Bio, and Kelun Biotech in relation to their respective therapies [4][7] - The report emphasizes the importance of survival data for ZL-1310 to validate its potential in the market [1][8] This summary encapsulates the critical developments and insights from the conference call, highlighting the advancements in cancer therapies and their implications for the market and investment opportunities.

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Tianfang Pharmaceutical, has received a drug registration certificate for Clopidogrel Hydrogen Sulfate Tablets, which is expected to enhance the company's cardiovascular medication product line and provide valuable experience for future generic drug development [1][6]. Group 1: Drug Registration Information - The drug name is Clopidogrel Hydrogen Sulfate Tablets, with a specification of 75mg [1]. - The registration application was accepted by the National Medical Products Administration (NMPA) in January 2024 [3]. - The total investment in the drug development has reached approximately 19.54 million RMB (about 2.95 million USD) [4]. Group 2: Market Situation - As of the announcement date, 21 other companies, including Shijiazhuang Yiling Pharmaceutical, Shenzhen Mindray Bio-Medical Electronics, and Zhejiang Jingxin Pharmaceutical, have also obtained production licenses for this drug [5]. - Clopidogrel Hydrogen Sulfate Tablets are classified as a Category B drug under the medical insurance system, with total domestic sales of approximately 4.924 billion RMB (about 0.74 billion USD) in 2023 and projected sales of about 5.376 billion RMB (about 0.81 billion USD) in 2024 [5].

证券代码：600056 证券简称：中国医药 公告编号：临 2025-043 号 中国医药健康产业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的一份硫酸氢氯吡格雷片（以下简称"该药品"） 《药品注册证书》，现将有关情况公告如下： 一、注册证书基本信息 剂型：片剂 规格：75mg（按 C16H16ClNO2S 计） 上市许可持有人：天方药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 （一）硫酸氢氯吡格雷片是赛诺菲制药研制的一种新型高效的血小板抑制剂， 于 1997 年经 FDA 批准在美国首次上市，于 2001 年 8 月在中国获准上市。主要用 于近期心肌梗死患者、近期缺血性卒中患者或确诊外周动脉性疾病患者 ...

Group 1 - The legal opinion letter confirms that the procedures for convening and holding the shareholders' meeting comply with the Company Law, Shareholders' Meeting Rules, and the company's articles of association [2][3][4] - The shareholders' meeting was scheduled for May 28, 2025, with a registration date of May 21, 2025, and utilized both on-site and online voting systems [2][3] - A total of 648,953,202 shares, representing 43.3827% of the company's total shares, were represented at the on-site meeting, while 152,601,156 shares, representing 18.0182% of the voting shares, participated in the online voting [3][4] Group 2 - The voting process involved both on-site and online methods, with a total of 151,129,549 shares voting in favor, accounting for 99.0356% of the valid votes cast [5] - The results from minority investors showed that 11,129,549 shares voted in favor, representing 88.3216% of the valid votes from minority shareholders [5] - The legal opinion concludes that the meeting's procedures, participant qualifications, voting methods, and results are all valid and comply with relevant laws and regulations [5][6]

Meeting Details - The 27th meeting of the 9th Board of Directors of China National Pharmaceutical Group Co., Ltd. was held on May 28, 2025, combining in-person and communication methods [1] - The meeting was chaired by Chairman Yang Guang, with attendance from all 7 directors, meeting the legal requirements for validity [1] Resolutions Passed - The board approved the proposal to nominate Mr. Pan Zhen as a candidate for director, with a proposed monthly pre-tax salary of 7,500 yuan and an annual bonus based on performance, totaling no more than 130,000 yuan pre-tax [2] - The proposal to convene the third extraordinary general meeting of shareholders in 2025 was also approved, with unanimous support from all directors present [2]